BPC-157 10mg · Research brief

Peptide Sciences BPC 157: Lab-Tested Alternatives

Real Peptides Research TeamEditorial

Updated October 13, 202610 min read

42 WORDS

Short answer

Key takeaways

As of October 2026, the Peptide Sciences website is unreachable and its catalog is offline, so researchers searching Peptide Sciences BPC 157 cannot retrieve historical product pages or certificates.
BPC-157 is a 15-amino-acid pentadecapeptide with CAS number 137525-51-0, molecular formula C62H98N16O22, and a molecular weight of roughly 1419.5 g/mol.
A certificate of analysis is only meaningful when its lot number matches the vial label and it reports both HPLC purity and mass spectrometry identity.
Chromatographic purity and net peptide content measure different things, and a vial can show high purity while containing less peptide by weight than the label implies.
BPC-157 sits in FDA Category 2 of bulk drug substances for 503A compounding and has been on the WADA Prohibited List under class S0 since 2022; it is not an approved drug.
Research-use-only suppliers do not provide dosing or preparation guidance, and Real Peptides publishes per-lot certificates rather than one generic document.

As of October 2026, the Peptide Sciences website is unreachable and its catalog is offline, which means anyone searching for Peptide Sciences BPC 157 lands on nothing. For a lab that standardised on one vendor, the problem isn't placing a new order. It's that the lot documentation, the certificate archive, and the product page referenced in a methods file went offline with it.

We supply research-use-only peptides to laboratories, and our team has worked with researchers who hit exactly this wall: a study halfway through a series, a vial of BPC-157 nearly empty, and no way to retrieve the paperwork that tied that material to its analysis. Here's what actually matters when you replace a supplier.

Where can researchers source BPC-157 now that Peptide Sciences BPC 157 is offline?

Researchers searching Peptide Sciences BPC 157 as of October 2026 will find the site unreachable and the catalog unavailable. Any replacement should be assessed on three verifiable points: a per-lot certificate of analysis whose lot number matches the vial label, HPLC purity paired with mass spectrometry identity confirmation, and the correct CAS number, 137525-51-0.

The common oversimplification is that BPC-157 is BPC-157, so one vendor substitutes cleanly for another. Sequence identity is the floor, not the proof. Two vials can both contain the correct 15-amino-acid pentadecapeptide and still differ in impurity profile, net peptide content by weight, and whether anyone independent actually measured either. What follows covers the verifiable status of the vendor, what the published BPC-157 literature reports, how to audit a replacement supplier's documentation, and where the regulatory lines sit.

Peptide Sciences BPC 157: what is verifiable as of October 2026

As of October 2026, the only verifiable facts about Peptide Sciences BPC 157 are that the company's website does not resolve and its product catalog is no longer accessible online. We won't speculate about why, and we won't pretend the company was anything other than what it was: a long-standing, widely used research supplier that a large number of labs bought BPC-157 from without incident.

The practical consequences are documentation consequences. There's no product page to cite, no portal to pull a historical certificate from, and no way to reorder a matching lot of the same material. If a study series ran across two lots and you only ever saved the first certificate, that gap is now permanent.

So the first action isn't sourcing. It's archiving. Pull down every order confirmation email, saved certificate PDF, and vial label photograph you still hold and store them locally with the study file. Our team has watched researchers reconstruct six months of lot history from an email receipt and a phone photo of a label, and watched others lose the thread completely because everything lived on a vendor site they assumed would always be there. When you do switch, record both vendors side by side in the methods log: CAS number, stated purity, analytical method used, lot number, and the date the certificate was issued. A supplier change mid-series is a variable. Documented, it's a footnote. Undocumented, it's a hole in the data.

What the published BPC-157 literature actually reports

BPC-157 is a synthetic pentadecapeptide, meaning a chain of exactly 15 amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a partial sequence of a protein described in human gastric juice and referred to in the literature as body protection compound. Its CAS registry number is 137525-51-0, its molecular formula is C62H98N16O22, and its molecular weight is approximately 1419.5 g/mol. Those four identifiers are the fastest sanity check on any listing you're considering.

The published research is predominantly rodent and in vitro work. Studies report angiogenic signalling effects, with the literature describing upregulation of VEGFR2 (vascular endothelial growth factor receptor 2) and downstream Akt and eNOS activity, the pathway that governs nitric oxide production in vascular endothelium. Separate tendon fibroblast work describes effects on the FAK-paxillin pathway, which governs cell adhesion and migration. Research also reports relative stability of the peptide in gastric juice compared with many other short peptides, which is part of why it attracted attention as a research subject in the first place.

What the literature does not contain is a body of large human clinical trial data. BPC-157 is not an approved drug, and nothing above is a claim about what it does in a person. Our team's position on this is consistent and boring: the mechanism language belongs to the published models it came from, and the compound is supplied for laboratory research only.

Reading a certificate of analysis like an auditor, not a buyer

The mistake most buyers make isn't ignoring certificates of analysis. It's reading only the purity percentage and stopping there. A certificate is a matching exercise, not a trust badge.

Three cross-checks do most of the work. First, the lot number printed on the certificate must match the lot number on the vial in your hand. A generic certificate with no lot number, or one that doesn't match, documents somebody else's material. Second, the certificate should carry two orthogonal methods: HPLC for chromatographic purity and mass spectrometry for identity. Purity alone tells you how clean something is. Mass confirmation tells you what it is. You need both, because a 99% pure wrong molecule is still the wrong molecule. Third, check the issue date against the synthesis date.

Here's the distinction almost no listing explains. Chromatographic purity and net peptide content are different measurements. HPLC purity describes what fraction of the peptide-related material in the vial is the target sequence. Net peptide content describes how much of the vial's total weight is actually peptide, after accounting for residual water and counterions such as trifluoroacetate left over from purification. A vial can report 99% HPLC purity and still contain meaningfully less peptide by mass than the label suggests, because the remaining weight is salt and moisture. Suppliers that publish net peptide content alongside purity are telling you something the purity number alone can't.

Regulatory status, storage, and what research use only actually constrains

BPC-157 is not an approved drug product. The FDA placed BPC-157 into Category 2 of its bulk drug substances list, the category for substances that raise significant safety risks, in the context of compounding under section 503A, following its review published in 2023. The World Anti-Doping Agency added BPC-157 to the Prohibited List under class S0, non-approved substances, effective in 2022. Both are matters of public record and both are worth knowing before a compound enters a facility.

Handling is straightforward and strict. Lyophilised peptide is a dry, hygroscopic powder that should be held at -20°C, protected from light and moisture, with cold chain maintained in transit. Temperature excursions and moisture ingress degrade peptides in ways no visual inspection catches, which is why shipping conditions belong in the supplier evaluation rather than being treated as logistics trivia.

What research use only constrains is what a supplier may tell you. Real Peptides does not publish dosing, preparation, or administration guidance for any catalog compound, because those are study parameters that belong to the investigator and their institutional protocol, not to the vendor. We'll tell you the molecular identity, the analytical data, the storage conditions, and the lot history. The information in this article is educational and describes published research and laboratory handling only.

Supplier evaluation criteria compared

This table is the checklist we'd apply to any vendor, including our own listings, when Peptide Sciences BPC 157 is no longer an option. Use it on the product page before you use it on a support email.

Verification point	Weak signal	Verifiable signal	Bottom line
Molecular identity	Listing shows a product name and a milligram figure only	CAS 137525-51-0, full 15-amino-acid sequence, molecular formula and weight published on the page	If the identifiers aren't on the listing, you can't confirm what you're ordering before it ships
Certificate of analysis	A single undated PDF reused across all lots, or COA available on request	A per-lot certificate whose lot number matches the vial label, publicly accessible before purchase	Per-lot certificates are the difference between documentation and decoration
Analytical methods	Purity percentage stated with no method named	HPLC purity plus mass spectrometry identity, with net peptide content reported separately	Two orthogonal methods confirm both cleanliness and identity; one method confirms neither on its own
Synthesis and batching	No information on where or how material is produced	Small-batch synthesis with exact amino acid sequencing and batch records retained	Small batches make lot-level traceability practical rather than theoretical
Origin and cold chain	Vague international dispatch, no storage conditions listed	US-based fulfilment with stated storage at -20°C and cold chain handling in transit	Shorter, documented transit reduces the temperature excursion risk you cannot test for after delivery

What If: Sourcing Scenarios

What if my lab was mid-study when the supplier went offline?

Freeze the documentation first, then source the replacement. Record the final lot number, stated purity, and analytical method from whatever paperwork you still hold, and log the switch date in the study file before new material arrives. A vendor change mid-series is defensible when it's documented and indefensible when it's discovered later by a reviewer. Where the protocol allows, running the remaining arm on a single new lot is cleaner than splitting it across two.

What if the replacement vial looks different from the previous lot?

Stop and compare certificates before anything else. Lyophilised peptide cake appearance varies legitimately with lyophilisation cycle, fill volume, and vial geometry, so a flatter or more fragmented cake is not automatically a quality signal. What is a signal: discolouration, visible moisture, or a certificate whose lot number doesn't match the label. Appearance is weak evidence. The certificate and the mass spectrometry identity data are strong evidence, and they're the only comparison worth making.

What if the certificate of analysis has no lot number or date?

Treat it as a marketing document and ask for the lot-specific version. An undated certificate without a lot reference cannot be tied to the material in front of you, which means it provides no traceability at all. Reputable research suppliers retain batch records and can produce the matching certificate on request; if a vendor cannot, that tells you how their batching and record-keeping actually work. We publish certificates by lot precisely so this question never needs to be asked.

What if a listing shows no CAS number anywhere?

Don't proceed on the product name alone. CAS 137525-51-0 is the registry identifier for BPC-157, and its absence from a listing means the only thing identifying the compound is a label. Cross-check the CAS number, the 15-amino-acid sequence, and the molecular weight against the certificate before procurement, not after delivery. Three independent identifiers agreeing is a reasonable confidence threshold. One product name agreeing with itself is not.

The uncomfortable truth about research peptide purity claims

Here's the honest answer: a purity figure printed on a product page with no per-lot certificate behind it is a number, not a measurement. Anyone can type 99%. What's expensive is synthesising in small batches, testing every lot by HPLC and mass spectrometry, and publishing the result where a buyer can check it against the vial before they order. That gap is where most of the research peptide market lives. The question worth asking any supplier isn't whether their material is pure. It's whether they'll show you the specific lot data for the specific vial they're shipping you.

Researchers comparing options can review the catalog listing for BPC-157 and the BPC-157 capsules format, read the broader BPC-157 research overview, check published certificates of analysis lot by lot, browse the full research peptide catalog, or review facility and shipping information. All compounds are supplied for laboratory research use only.

Peptide Sciences BPC 157 going offline is a procurement problem for a week and a documentation problem for years. The vial gets replaced easily. What doesn't is the chain of evidence connecting a published result to the material that produced it, and that chain is only as strong as the lot-level paperwork you can still open three years from now. Choose a supplier the way you'd choose an instrument: on whether its output can be independently verified by someone with no reason to trust you. Real Peptides is not affiliated with Peptide Sciences.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

As of October 2026, the Peptide Sciences website is unreachable and its product catalog is offline, so the BPC-157 listing cannot be accessed or ordered. The company was a long-standing and widely used research supplier, and we're not speculating about the reason for the outage. Researchers who purchased previously should archive any order confirmations, certificates, or vial label photographs they still hold locally, because the vendor portal is no longer a source for that documentation.

Real Peptides is a US-based research peptide supplier offering BPC-157 for laboratory research use only, with small-batch synthesis, exact amino acid sequencing, and per-lot certificates of analysis that are publicly accessible. Because the Peptide Sciences catalog is offline as of October 2026, a direct listing-to-listing comparison is no longer possible. The practical evaluation criteria remain the same for any supplier: matching CAS number, lot-specific certificates, and both HPLC purity and mass spectrometry identity data.

Start by matching the lot number on the certificate to the lot number printed on the vial label; if they don't match, the certificate documents different material. Next, confirm the certificate reports two orthogonal methods, HPLC for chromatographic purity and mass spectrometry for identity confirmation. Finally, check the CAS number 137525-51-0 and the molecular weight of approximately 1419.5 g/mol against the listing. A certificate without a lot number or an issue date provides no traceability.

BPC-157 carries CAS registry number 137525-51-0, with molecular formula C62H98N16O22 and a molecular weight of roughly 1419.5 g/mol. The peptide is 15 amino acids long with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. If a listing shows none of these identifiers, there is no way to confirm the molecular identity of what's being sold before it arrives.

BPC-157 is supplied as a research-use-only compound intended for laboratory research by researchers and institutions, and it is not sold for human or veterinary use. It is not an approved drug product. The FDA placed BPC-157 into Category 2 of its bulk drug substances list, the category for substances raising significant safety risks, in the context of 503A compounding following its 2023 review.

Cost differences usually track what the supplier is actually paying for, rather than the compound itself. Small-batch synthesis, per-lot third-party analytical testing, net peptide content reporting, retained batch records, and maintained cold chain shipping all add real cost per vial. A listing without lot-specific certificates has removed several of those cost centres, which is often what the price gap represents.

HPLC purity describes what fraction of the peptide-related material in a vial is the target sequence, expressed as a percentage of the chromatographic signal. Net peptide content describes how much of the vial's total weight is actually peptide, after accounting for residual moisture and counterions such as trifluoroacetate left behind during purification. A vial can report very high HPLC purity while containing less peptide by mass than the label weight implies, which is why both figures matter.

No. Real Peptides does not provide dosing, preparation, administration, or protocol guidance for any catalog compound, because these are research-use-only materials and study parameters belong to the investigator and their institutional protocol. What we do publish is molecular identity data, per-lot analytical results, and storage conditions. Lyophilised peptide is held at -20°C, protected from light and moisture, with cold chain maintained in transit.

The main risks are identity and traceability failures rather than anything visible on arrival. Without mass spectrometry identity confirmation, there is no way to confirm the vial contains the stated 15-amino-acid sequence, and without a lot-matched certificate there is no way to tie analytical data to the specific material received. Temperature excursions during shipping degrade peptides invisibly, so storage and transit conditions are part of the risk assessment, not a logistics footnote.

The published literature is predominantly rodent and in vitro work. Studies report angiogenic signalling effects, with research describing upregulation of VEGFR2 (vascular endothelial growth factor receptor 2) and downstream Akt and eNOS activity, the pathway governing nitric oxide production in vascular endothelium. Tendon fibroblast studies describe effects on the FAK-paxillin pathway, which governs cell adhesion and migration. Large human clinical trial data is not part of this body of work, and BPC-157 is not an approved drug.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA